Provided is a stable pharmaceutical composition, comprising an anti-human TSLP receptor antibody, capable of inhibiting the generation of chemically modified substances, such as deamidated forms and oxidized forms, or degradants or multimers. The pharmaceutical composition comprises an anti-human TSLP receptor antibody, a pharmaceutically acceptable buffer, arginine or a pharmaceutically acceptable salt thereof, and a surfactant.

Provided is a stable pharmaceutical composition, comprising an anti-human TSLP receptor antibody, capable of inhibiting the generation of chemically modified substances, such as deamidated forms and oxidized forms, or degradants or multimers. The pharmaceutical composition comprises an anti-human TSLP receptor antibody, a pharmaceutically acceptable buffer, arginine or a pharmaceutically acceptable salt thereof, and a surfactant.

A composition for the treatment of Demodex blepharitis and/or acne containing tea tree oil (TTO), coconut oil, aloe barbadensis, decyl glucoside, sodium chloride, sodium lauroyl methyl isethionate, Caprylic/Capric Triglyceride, Caprylyl Glycol, Ethylhexylglycerin, and Hexylene Glycol in glycerin or in water or in a mixture of glycerin and water. The composition is used to treat Demodex blepharitis and/or acne by applying the composition to the eyelid margin and eyelashes or acne and scrubbing the eyelid margin, eyelashes, and eyelash roots or acne with the composition using any suitable cloth, wipe, sponge, brush, or cotton tipped applicator.

A composition for the treatment of Demodex blepharitis and/or acne containing tea tree oil (TTO), coconut oil, aloe barbadensis, decyl glucoside, sodium chloride, sodium lauroyl methyl isethionate, Caprylic/Capric Triglyceride, Caprylyl Glycol, Ethylhexylglycerin, and Hexylene Glycol in glycerin or in water or in a mixture of glycerin and water. The composition is used to treat Demodex blepharitis and/or acne by applying the composition to the eyelid margin and eyelashes or acne and scrubbing the eyelid margin, eyelashes, and eyelash roots or acne with the composition using any suitable cloth, wipe, sponge, brush, or cotton tipped applicator.

A method of manufacturing a high molecular weight heparin (HMWH) compound is disclosed. The method comprises dissolving heparin to form a heparin solution and fractionating the heparin solution via tangential flow filtration (TFF) using a membrane with a molecular weight cut off (MWCO) between about 8 kDa and about 12 kDa. The TFF yields a retentate comprising fractionated heparin with a weight average molecular weight of about 20 kDa or greater, i.e., a high molecular weight heparin compound. A substantial proportion of heparin chains in the fractionated heparin may have a high molecular weight, e.g., 50% of the heparin chains or greater may have a molecular weight of 20 kDa or greater.

A method of manufacturing a high molecular weight heparin (HMWH) compound is disclosed. The method comprises dissolving heparin to form a heparin solution and fractionating the heparin solution via tangential flow filtration (TFF) using a membrane with a molecular weight cut off (MWCO) between about 8 kDa and about 12 kDa. The TFF yields a retentate comprising fractionated heparin with a weight average molecular weight of about 20 kDa or greater, i.e., a high molecular weight heparin compound. A substantial proportion of heparin chains in the fractionated heparin may have a high molecular weight, e.g., 50% of the heparin chains or greater may have a molecular weight of 20 kDa or greater.

The present invention relates to a composition comprising, preferably consisting of, (i) a single empty liposome, wherein said single empty liposome is selected from (a) an empty liposome consisting of sphingomyelin and cholesterol, wherein the amount of cholesterol is at least 20% (weight per weight); or (b) an empty liposome consisting of sphingomyelin; or (ii) a mixture of empty liposomes; wherein said mixture of empty liposomes comprises (a) a first empty liposome consisting of sphingomyelin and cholesterol, wherein the amount of cholesterol is at least 20% (weight per weight); and (b) a second empty liposome consisting of sphingomyelin; for use in a method of treating or preventing a viral infection in a mammal, preferably in a human.

Methods of preparing and administering an injectable depot formulation of crystalline iloperidone are disclosed herein.

Methods of preparing and administering an injectable depot formulation of crystalline iloperidone are disclosed herein.

A composition comprising a hydrogen peroxide source and at least one metal halide. The hydrogen peroxide source comprises hydrogen peroxide and a means for generating hydrogen peroxide. The means for producing hydrogen peroxide comprises at least one oxidoreductase and at least one oxidoreductase substrate. The oxidoreductase substrate comprises at least one sugar, said sugar located within the composition. The composition is held under conditions that render the components inactive until rehydrated.